WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the company will have a poster presentation showcasing preclinical data for EDP-721, a novel, potent and selective oral HBV RNA destabilizer being developed for use in an all-oral functional cure of hepatitis B virus, at the upcoming European Association for the Study of the Liver’s (EASL) International Liver Congress 2021, being held virtually June 23-26, 2021.
Details of the poster presentation are as follows:
Date/Time: June 23, 2021, 08:00 CET
Poster 942: Discovery and characterization of EDP-721, a novel hepatitis B virus RNA destabilizer
Session Name: Viral Hepatitis B/D: Therapy
Presenter: Michael Vaine, Ph.D., United States
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.